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Introduction
Mixed Connective Tissue Disease (MCTD) is a rare auto-
immune disease of unknown origin. The diagnosis is sug-
gested when there are overlaping symptoms of lupus,
scleroderma and dermatomyositis. Kasukawa criteria are
the most commonly used in pediatrics. Treatment should
be tailored to the clinical symptoms but no specific recom-
mendation regarding the therapeutic management has
been established to date.
Tocilizumab (TCZ), an inhibitor of interleukin 6 is
used in juvenile idiopathic arthritis (systemic and polyar-
ticular JIA) and Castleman’s disease. Only one case has
been reported with TCZ in the context of a MCTD with
pulmonary hypertension in a 45 year-old man with a
favorable outcome.
Objectives
We report on two children diagnosed for a MCTD who
presented with active arthritis despite various therapies
including methotrexate (MTX) and TNFa blockers.
Methods
Description of two clinical cases.
Results
Case 1
A 7 year-old girl was initially diagnosed for a polyarticular
JIA and was in remission under MTX and etanercept
(ETA) combination. 8 years later (at the age of 15), she pre-
sented with a relapse with Raynaud’s phenomenon, sclero-
dactily and polyarticular arthritis. Laboratory tests revealed
the presence of ANA (1/1600), positive anti-DNAdb
(30 UI/l) and positive anti-ENA (anti Sm–RNP at >8 UA/
ml and anti U1RNP at >8 UA/ml). Because of low toler-
ance to MTX and joint manifestations in the foreground,
treatment with TCZ was initiated. The joint outcome
under treatment was shortly favorable. Regarding other
autoimmune manifestations, the evolution was marked by
the appearance of positive Coombs test with asymptomatic
anemia, neutropenia, mixed, and an increase of anti-DNA
titer. Other treatments consisted in a low dose steroids and
hydroxychloroquine (HCQ).
Case 2
A 12 year-old girl presented with juvenile dermatomyositis
and was successfully treated by steroids and MTX. 2 years
later, she presented a relapse with Raynaud’s phenomenon,
sclerodactily, and a Gougerot-Sjögren’s syndrome. Auto-
antibody screening revealed positive ANA (1/1600) with
anti-DNA 7,4 (Farr assay) and positive anti-ENA (anti
-SSA, anti -Sm, anti- SmRNP and anti- U1RNP). Various
therapies including MTX, mycophenolate mofetil, HCQ,
ETA did not manage to control articular symptoms. TCZ
in combination with MTX was started at the age of 17
and was shortly associated to remission. Other manifesta-
tions, including Raynaud’s syndrome and liver disease,
tended to persist. Other therapies consisted in a low dose
steroids and HCQ with irregular compliance.
Conclusion
This is the first description of the use of TCZ for articular
manifestations of pediatric-onset MCTD. These two
observations suggest that TCZ is effective and safe on
articular manifestations of MCTD. However, systemic
autoimmune manifestations including leucopenia and
hepatitis were not improved by the treatment.
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